Back to EveryPatent.com
United States Patent | 5,631,243 |
Kelman ,   et al. | May 20, 1997 |
The present invention relates to a method of treating a patient with visco-surgery, particularly ocular visco-surgery, utilizing a collagen-based viscoelastic solution having a reversibly high viscosity. The invention also relates to collagen-based viscoelastic solutions which further include mucopolysaccarides or growth factors.
Inventors: | Kelman; Charles D. (New York, NY); DeVore; Dale P. (Chelmsford, MA) |
Assignee: | Collagenesis Inc. (Acton, MA) |
Appl. No.: | 365167 |
Filed: | December 28, 1994 |
Current U.S. Class: | 514/56; 424/427; 514/2; 514/21; 514/54; 514/62; 514/801; 514/912; 604/521 |
Intern'l Class: | A61K 031/725; A61K 031/715; A61M 031/00 |
Field of Search: | 514/56,54,2,21,62,912,801 536/4.1,123,119,55.1 530/356 623/4 424/427 128/DIG. 8 604/48,51 |
Re32969 | Jun., 1989 | Trager et al. | 514/912. |
2827419 | Mar., 1958 | Tourtellott et al. | 514/801. |
3034852 | May., 1962 | Nishihara | 435/68. |
3314861 | Apr., 1967 | Fujii et al. | 435/68. |
4141973 | Feb., 1979 | Balazs | 536/4. |
4328803 | May., 1982 | Pape | 514/54. |
4418691 | Dec., 1983 | Yannas et al. | 623/15. |
4581030 | Apr., 1986 | Bruns et al. | 623/4. |
4582865 | Apr., 1986 | Balazs et al. | 524/29. |
4663166 | May., 1987 | Veech | 514/23. |
4705682 | Nov., 1987 | Moeller et al. | 252/356. |
4713446 | Dec., 1987 | DeVore et al. | 514/801. |
4748152 | May., 1988 | Miyata et al. | 424/427. |
4819617 | Apr., 1989 | Goldberg et al. | 536/98. |
4851513 | Jul., 1989 | DeVore et al. | 514/801. |
4882284 | Nov., 1989 | Kirchanski et al. | 436/172. |
4883864 | Nov., 1989 | Scholz | 514/21. |
4929242 | May., 1990 | Desecki et al. | 604/266. |
Dijke et al., Biotechnology, vol. 7, Aug. 1989, pp. 793-798. K.H. Stenzel et al. (1967), "Collagen-Derived Membrane: Corneal Implantation", Science, vol. 157, pp. 1329-1330. K.H. Stenzel et al. (1969), "Collagen Gels: Design for a Viteous Replacement", Science, vol. 164, pp. 1282-1283. A.L. Rubin et al. (1965), "Effects of Pepsin Treatment on the Interaction Properties of Tropocollagen Macromolecules", Biochemistry, vol. 4 (2), pp. 181-189. Devore Dale P. et al., Rheology of Sodium Hyaluronate Solutions and Relevance to Their Use as Medical Implants, Mat. Res. Soc. Proc. vol. 110, pp. 455-461. Arshinoff S.A., Viscoelastic Substances: Their Properties and Use When Placing An Iol in the Capsular Bag, Curr. Can. Ophthalmic Prac. 4:2, 64-65 and 72-74, 1986. MacRae et al., The Effects of Sodium Hyaluronate, Chondroitin Sulfate and Methylcellulose on the Corneal Endothelium and Intracular Pressure, Amer. J. Ophthal. 95:332-341, 1983. Balasz, E., Sodium Hyaluronate and Viscosurgery, Healon, Miller, D. and Stegman, R., eds. John Wiley & Sons, New York, 1983, pp. 5-28. Lutjen-Drecoll, E., ARVO Annual Meeting Abstracts, Apr. 29-May 4, 1990, Association for Research in Vision and Ophthalmology, vol. 31(4), p. 184. Dijke et al., Bio/Technology, 7:793-798, 1989. The Methodology of Connective Tissue Research, D. Hall, ed., Joynson-Bruvvers, Ltd., Oxford, p. 227. Bitter & Muir, Anal. Biochem., 4:330, 1962. |
TABLE I ______________________________________ Viscoelastic Collagen Solution Specifications Characteristic Acceptable Preferred ______________________________________ Osmolarity 305 .+-. 100 m Osmol 305 .+-. 25 m Osmol pH 7.4 .+-. 0.6 7.4 .+-. 0.4 Color -- Colorless Viscosity 1,000-500,000 cps.sup.a 45,000-80,000 cps Endotoxin <500 Eu/ml.sup.b <5 Eu/ml Collagen <10% (w/v) <2.0% (w/v) Concentration Melt Temperature 5-100.degree. C. 30-40.degree. C. Sterility Sterile Sterile Ionic Strength .ltoreq.0.001.mu. .ltoreq.0.0008.mu. ______________________________________ .sup.a At a shear rate of 1 sec.sup.-2. .sup.b Eu = endotoxin units.
TABLE II __________________________________________________________________________ Intraocular Pressure/mm Hg Pre- Injection 1 hour 3 hours 5 hours 24 hours 48 hours __________________________________________________________________________ LOT A Rabbit 1: 19.8 10.1 25.0 21.7 11.8 21.0 Rabbit 2: 21.3 7.9 10.8 14.3 11.6 31.0 Rabbit 3: 19.7 11.0 21.9 22.3 29.8 22.2 Mean .+-. SD: 20.2 .+-. .7 9.7 .+-. 1.6 19.2 .+-. 7.5 19.4 .+-. 4.5 17.7 .+-. 10.5 24.7 .+-. 5.5 VISCOAT .TM. Rabbit 1: 15.5 9.1 41.1 31.1 10.7 24.0 Rabbit 2: 23.1 36.8 9.6 8.5 8.4 31.1 Rabbit 3: 11.9 8.1 40.1 14.6 14.0 24.3 Mean .+-. SD: 16.8 .+-. 5.7 18.0 .+-. 16.3 30.3 .+-. 18.0 18.1 .+-. 11.7 11.0 .+-. 2.8 26.5 .+-. 4.0 __________________________________________________________________________
TABLE III __________________________________________________________________________ Intraocular Pressure/mm Hg Pre- Injection 1 hour 3 hours 5 hours 24 hours 48 hours __________________________________________________________________________ LOT A' Rabbit 1: 32.9 9.4 12.1 13.8 19.2 3.4 Rabbit 2: 20.7 20.6 38.5 34.8 33.5 30.7 Rabbit 3: 23.3 30.3 32.8 26.5 37.8 19.4 Mean .+-. SD: 25.6 .+-. 6.4 20.1 .+-. 10.5 27.8 .+-. 18.9 25.0 .+-. 10.6 30.2 .+-. 9.7 28.0 .+-. 7.7 HEALON .TM. Rabbit 1: 16.0 7.9 6.1 7.8 20.1 10.8 Rabbit 2: 15.3 13.7 16.2 26.0 34.5 16.3 Rabbit 3: 19.0 6.4 15.3 25.2 15.5 18.6 Mean .+-. SD: 16.7 .+-. 2 9.3 .+-. 3.9 12.5 .+-. 5.6 19.7 .+-. 10.3 23.4 .+-. 9.9 15.2 .+-. 4.0 __________________________________________________________________________